Frontiers in Pharmacology retracted a 2022 fisetin study after image integrity concerns and an audit flagged previously published image reuse. The journal concluded that the underlying data and primary conclusions could no longer be considered reliable. Retractions like this are operationally relevant for biotech teams that rely on preclinical literature for target selection, assay design, and translational hypotheses. The event also reinforces the need for internal data verification when building programs around published mechanisms and efficacy claims.